PriorixTM

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaMeaslesMumpsPoliomyelitisRubellaTetanusVaricella

Phase 3

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

CompletedNCT00751348

GlaxoSmithKlineMeasles, Mumps, Rubella +1

Start: 2008-10-01End: 2010-05-27Updated: 2018-06-08

Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

CompletedNCT01245049

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Poliomyelitis +1

Start: 2011-04-01End: 2012-04-02Updated: 2018-08-17

Related Papers

A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK

Vaccine2018-03-2316 citations

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children.

2013-12-187 citations